Altimmune Announces Dosing of First Patient in Phase 1b Clinical Trial of NasoShield™, a Single Dose Intranasal Anthrax Vaccine Candidate
Go back to Altimmune Announces Dosing of First Patient in Phase 1b Clinical Trial of NasoShield™, a Single Dose Intranasal Anthrax Vaccine Candidate| iShares Diversified Alternatives Trust (NASDAQ: ALT) | Delayed: 3.11 -0.13 (4.01%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.24 | 52 Week High | $54.24 | |||
| Open | $3.21 | 52 Week Low | $48.35 | |||
| Day High | $3.23 | P/E | N/A | |||
| Day Low | $3.06 | EPS | $0.00 | |||
| Volume | 3,193,514 | |||||
